Drug Makers: Valeant’s M&A Prospects in 2016

Don’t’ expect lots of M&A from Valeant Pharmaceuticals (VRX) in 2016. The controversial drug company’s rapid, acquisition-driven expansion made it a friend to investment banks. It was the fifth-largest payer of investment banking fees over the past three years, according to Reuters. Yet at a recent $102 a share, the stock has fallen 61% since […]